FENC PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

FENC ▲ +5.22% at T+20d

NEUTRAL call ✓ call won +5.22% · α vs SPY -4.56% · entry $6.32 → $6.65

Next anchor: T+60d in 17d

Last close $9.00 (close Jun 12) · +42.41% from $6.32 entry

Entry anchored
Apr 6, 03:59 PM ET
via Databento tick

T+1d

+2.69%

call +2.69% · α +0.15%

$6.49

settled 2mo ago

T+5d

-1.11%

call -1.11% · α -6.44%

$6.25

settled 2mo ago

T+20d

+5.22%

call +5.22% · α -4.56%

$6.65

settled 6w ago

T+60d

—

call — · α —

—

in 17d

Price Chart

Loading chart...

Executive Summary

Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study at the University of Arizona Cancer Center evaluating PEDMARK® in adolescent and adult patients with solid tumors receiving cisplatin chemotherapy. This adds to recent institutional studies at Tampa General Hospital and City of Hope, expanding real-world validation of PEDMARK® beyond its current pediatric indication. The company continues to build evidence for potential label expansion into adult populations.

Actionable Insight

Monitor for future data readouts from these investigator-initiated trials, which could support regulatory discussions for label expansion. Increased real-world use in AYA and adult populations may drive off-label adoption and commercial growth.

Key Facts

University of Arizona Cancer Center has initiated a Phase I/II trial of PEDMARK® in AYA and adult patients with head and neck and testicular cancers receiving cisplatin.
This is the third institution-led study announced in recent months, following Tampa General Hospital and City of Hope.
PEDMARK® is currently FDA-approved only for pediatric patients, but has a 2A NCCN recommendation for use in AYA patients.
The study will assess efficacy in reducing hearing impairment and systemic elimination of unbound cisplatin.

Financial Impact

No immediate financial impact disclosed; potential long-term revenue expansion if label is broadened to adults.

revenuemarket adoption

Risk Factors

Regulatory approval for adult indications is uncertain and may require additional clinical data.
Potential safety or efficacy issues in adult populations not seen in pediatric trials.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3268978

13 reports for FENC

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+60▲ +20.32%Feb 28, 2026

Filters

Reports for FENC — sortable, filterable
	Type				Now
May 22, 2026 23d ago	8-K NEUTRAL ★ 4/10	$9.89 $9.88	▼ −0.10%	▼ −1.18%	$9.00 (−9.00%)
May 18, 2026 27d ago	8-K NEUTRAL ★ 2/10	$9.76 $9.97	▲ +2.15%	▼ −0.15%	$9.00 (−7.79%)
May 14, 2026 4w ago	Press Release BULLISH ★ 6/10	$9.24 $9.97	▲ +7.90%	▲ +8.62%	$9.00 (−2.60%)
May 7, 2026 5w ago	Press Release NEUTRAL ★ 2/10	$6.90 $6.77	▼ −1.88%	▼ −3.39%	$9.00 (+30.43%)
Apr 28, 2026 6w ago	8-K NEUTRAL ★ 2/10	$6.26 $7.18	▲ +14.70%	▲ +11.59%	$9.00 (+43.77%)
Apr 22, 2026 7w ago	8-K NEUTRAL ★ 3/10	$6.66 $6.26	▼ −6.01%	▼ −7.48%	$9.00 (+35.14%)
Apr 7, 2026 9w ago	8-K NEUTRAL ★ 4/10	$6.49 $6.50	▲ +0.15%	▼ −3.36%	$9.00 (+38.67%)
Apr 7, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$6.32 $6.25	▼ −1.11%	▼ −6.44%	$9.00 (+42.41%)
Mar 24, 2026 11w ago	Press Release BULLISH ★ 8/10	$6.02 $6.15	▲ +2.16%	▲ +2.58%	$9.00 (+49.50%)
Mar 18, 2026 12w ago	Press Release NEUTRAL ★ 3/10	$7.47 $6.17	▼ −17.40%	▼ −16.69%	$9.00 (+20.48%)

US Market Status

Market Closed — Opens in 4h 42m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access